FDA approves Lumigan eye drops to reduce intraocular pressure in patients with open angle glaucoma
Allergan, Inc (NYSE: AGN) announced today the States United Food and Drug Administration (FDA) approved Lumigan (bimatoprost ophthalmic solution) 0.01% for first-line therapy are indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. Lumigan 0,01% optimized reformulation of Lumigan (bimatoprost ophthalmic solution) 0.03%.
“Based on its efficacy and tolerability, Lumigan 0,01% should be considered in the early treatment of the continuum as an alternative to other prostaglandins, or therapies.”
“Adoption of Lumigan (bimatoprost ophthalmic) 0,01% provides physicians with an effective, safe and well tolerated IOP-lowering medications for patients with glaucoma who are either starting treatment or changing their medication regime,” said Scott Whitcup, MD, Allergan’s executive vice-president , Research and Development, Chief Scientific Officer. “Lumigan (bimatoprost ophthalmic) 0,01% Allergan illustrates the commitment to developing medicines for patients with glaucoma, which maximize efficiency while minimizing the effects of drugs.”
Lumigan 0,01% once-daily prescription eye drops, which provides effective and sustained reduction in IOP. In the three-month study of patients with open angle glaucoma or ocular hypertension with a mean baseline 23.5 mmHg, Lumigan 0,01% reduced IOP up to 7 mm Hg from baseline, and only one-third of drug exposure Lumigan 0,03% 1. The most common side effects of Lumigan (bimatoprost ophthalmic) 0,01% are hyperemia (redness of the eyes), growth of eyelashes and ocular pruritus (itchy eyes).
“Once a day, prostaglandins are therapy choices based on their performance, system security and ease of use,” said L. Jay Katz, MD, director of the Glaucoma Service at Wills Eye Hospital, professor of ophthalmology at Jefferson Medical College. “Based on its efficacy and tolerability, Lumigan (bimatoprost ophthalmic) 0,01% should be considered in the early treatment of the continuum as an alternative to other prostaglandins, or therapies.”
How Bimatoprost Ophthalmic work?
This is a difficult question moved most frequently asked questions on bimatoprost. Although the FDA has approved this novel treatment, there is very little known about how it works Bimatoprost. Its active ingredient bimatoprost lipid compound known as a structural analog of prostaglandin. Its effect is manifested in the form of mandatory prostaglandin (PG) receptors. It is believed that the effect of Bimatoprost in these PG receptors, which may be responsible for the growth process of hair follicles.
Side effects of Bimatoprost Ophthalmic
Bimatoprost side effects are generally seen as itching or redness in the eye. These symptoms usually disappear after a few days of regular use dose. Some other side effects of Bimatoprost, which were discovered at the site of application include darkening of the skin, eye dryness and irritation, and redness of the eyelids. These conditions are not too serious if the doctor prescribed dose of Bimatoprost is followed.
However, in some cases of overdose or sensitive patients, there are also dangerous consequences, including eye reactions. If you encounter any such problem, you should immediately talk to your doctor about a dosage adjustment or other medical alternatives. There is no information on the impact of Bimatoprost during pregnancy, and so these women should avoid using this medication.
Guide before taking Bimatoprost Ophthalmic
Bimatoprost comes with a free applicator, which can be used in at least 20 times. We sell a package of 30 and 60 applicators, if you do not have an applicator in your hand, you can use regular Qtips. Make sure to place them correctly and the reach of children. Bimatoprost should be used once a day, so that only the upper eyelid, there should be no use to the lower eyelid. While intended for use only on the eyelid, there is no danger if Bimatoprost gets in your eyes. However, this can lead to discoloration of your iris. Bimatoprost is intended for use in the long term for growth of eyelashes, if you stop using Bimatoprost then your lashes will return to a normal growth cycle stages.
What are the common dose of Bimatoprost Ophthalmic?
Bimatoprost is available in 3 ml pack and it includes a free applicator. Bimatoprost solution typically contains 0.03% active ingredient, bimatoprost.
The difference between a brand and Generic Bimatoprost Ophthalmic
The difference lies mainly in how it is packaged by various manufacturers. As the active ingredient bimatoprost remains the same, is rarely a difference in terms of efficiency. Nevertheless, the overall bimatoprost, tend to be cheaper, it does not carry a premium brand.